• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics Inc (NQ: IOVA )

    8.550 +0.310 (+3.76%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 9,273,849
    Open 8.150
    Bid (Size) 8.580 (12)
    Ask (Size) 8.610 (4)
    Prev. Close 8.240
    Today's Range 8.080 - 8.715
    52wk Range 5.410 - 18.33
    Shares Outstanding 304,780,790
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    2 Innovative Stocks That Could Deliver Outsize Returns
    Via The Motley Fool
    2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
    Via The Motley Fool

    Performance

    YTD
    +5.56%
    +5.56%
    1 Month
    -12.93%
    -12.93%
    3 Month
    -27.97%
    -27.97%
    6 Month
    -14.59%
    -14.59%
    1 Year
    +47.67%
    +47.67%

    More News

    Read More
    Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    A Peek at Iovance Biotherapeutics's Future Earnings
    Via Benzinga
    Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Is Iovance Biotherapeutics Stock a Buy?
    Via The Motley Fool
    (IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
    Via Benzinga
    Looking Into Iovance Biotherapeutics's Recent Short Interest
    Via Benzinga
    Why Iovance Biotherapeutics Stock Triumphed on Thursday
    Via The Motley Fool
    3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
    Via The Motley Fool
    3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
    Via The Motley Fool
    AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    This Is the Biggest Risk With Iovance Biotherapeutics Stock
    Via The Motley Fool
    Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
    Via Benzinga
    Iovance Biotherapeutics to Present at Upcoming Conferences
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    3 Monster Biotech Stocks to Buy Before 2025
    Via The Motley Fool
    Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
    Via The Motley Fool
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
    Via The Motley Fool
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Why Iovance Biotherapeutics Shares Are Soaring Today
    Via The Motley Fool
    Why Is Iovance Bio (IOVA) Stock Up 18% Today?
    Via InvestorPlace
    Topics Earnings
    Exposures Financial
    Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
    Via Benzinga
    Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.